There are currently 91 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
NCT06155500
Recruiting
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: St Jude Childrens Rsrch Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Study of the Role of Genetic Modifiers in Hemoglobinopathies
NCT05799118
Recruiting
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/19/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +25 locations
Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
Register for Updates
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia
NCT05214105
Recruiting
This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/13/2023
Locations: University of Illinois at Chicago, Chicago, Illinois +2 locations
Conditions: Sickle Cell Disease, Kidney Diseases, Chronic
Register for Updates
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
NCT01245179
Recruiting
The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F induction, which is well documented to improve outcomes in sickle cell disease. HDAC inhibitors are also known to potently inhibit cell-specific inflammation, which is a primary contributor to the debilitati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Sickle Cell Disease
Register for Updates
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
NCT05334576
Recruiting
In this prospective, single-arm, open-label, imaging and treatment study, the investigator will test the hypothesis that crizanlizumab will prevent the progression of silent cerebral infarcts in patients with sickle cell disease. Study participants will undergo brain MRI before initiation of crizanlizumab and at 6 and 30 months after starting crizanlizumab infusions. The crizanlizumab cohort will be compared to a matched, observational cohort of patients not receiving crizanlizumab.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/02/2023
Locations: Barnes-Jewish Hospital, Saint Louis, Missouri
Conditions: Sickle Cell Disease
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates